Zoekresultaten - Katherine Garlo

  • Toon 1 - 6 resultaten van 6
Verfijn jouw resultaten
  1. 1
    Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation

    Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation door Thomas A. Mavrakanas, Katherine Garlo, David M. Charytan

    Gepubliceerd in 2020
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Burden in Caregivers of Older Adults with Advanced Illness

    Burden in Caregivers of Older Adults with Advanced Illness door Katherine Garlo, John R. O’Leary, Peter H. Van Ness, Terri R. Fried

    Gepubliceerd in 2010
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY

    WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY door Jonathan Barratt, Miguel Ángel Pérez Valdivia, Dario Roccatello, Katherine Garlo, Kara Rice, Richard A. Lafayette

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Chronotype is associated with the timing of the circadian clock and sleep in toddlers

    Chronotype is associated with the timing of the circadian clock and sleep in toddlers door Charles T. Simpkin, Oskar G. Jenni, Mary A. Carskadon, Kenneth P. Wright, Lameese D. Akacem, Katherine Garlo, Monique K. LeBourgeois

    Gepubliceerd in 2014
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

    Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials door Bradley P. Dixon, David Kavanagh, Alvaro Domingo Madrid Aris, Brigitte Adams, Hee Gyung Kang, Edward Wang, Katherine Garlo, Masayo Ogawa, Praveen K. Amancha, S. Chakravarty, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung‐Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff‐Luett, Kazuki Tanaka, Larry A. Greenbaum

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

    Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults door Thomas Barbour, Marie Scully, Gema Ariceta, Spero Cataland, Katherine Garlo, Nils Heyne, Yosu Luque, Jan Menne, Yoshitaka Miyakawa, Sung‐Soo Yoon, David Kavanagh, Sunil Babu, Nilüfer Broeders, Nicole Lietar, Fiona G. Brown, Philip Campbell, Josep M. Campistol, Paramit Chowdhury, Theo Kasimatis, Lino Cirami, Leonardo Caroti, Guilia Antognoli, Yahsou Delmas, Vladimir Dobronravov, Anja Gaeckler, Cyril Garrouste, Gregory Greenwood, Siân Griffin, Chiu‐Ching Huang, I−Ru Chen, Susan S. Huang, Jin Seok Kim, Gaetano La Manna, Moglie Le Quintrec, Guillaume Jeantet, Iino Fumie, Éric Rondeau, Hermann Haller, J Morelle, Éric Goffin, Anja Mühlfeld, Shashi Nagaraj, Gowthami M. Arepally, Doyeun Oh, Masayoshi Okumi, Manuel Praga Terente, François Provôt, Ulf Schönermarck, Michael Fischereder, Natàlia Ramos Terrada, Barbara Seitz‐Polski, Guillaume Favrè, Sonia Boyer‐Suavet, Maria Vinogradova, Tatiana Kirsanova, Edwin Wong

    Gepubliceerd in 2021
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: